Single Injection of Three Different Preparations of α-Interferon Modifies Morphine Abstinence Signs for a Prolonged Period

References

• Abreu S. L., Canella M. S., Hanke J. Induction and cross‐species activity of rat fibroblast‐derived interferon. Microbioscience 1981; 30: 181–190
   PubMedGoogle Scholar
• Bell B. E. Cellular events in protein tolerant inbred rats. II. Antibody avidity maturation during induction and loss of tolerance. European Journal of Immunology 1973; 3: 267–272
   PubMed Web of Science ®Google Scholar
• Berkowitz B., Spector S. Evidence of active immunity to morphine in mice. Science 1972; 178: 1290–1292
   PubMed Web of Science ®Google Scholar
• Blalock J. E., Smith E. M. Human leukocyte interferon: Structural and biological relatedness to adrenocorticotropic hormone and endorphins. Proceedings of the National Academy of Science, USA 1980; 77: 5972–5974
   PubMed Web of Science ®Google Scholar
• Blalock J. E., Smith E. M. Human leukocyte interferon (HuIFN‐α): Potent endorphin‐like opioid activity. Biochemistry and Biophysics Research Communications 1981; 101: 472–478
   PubMed Web of Science ®Google Scholar
• Blasig J., Hem A., Reinhold K., Zieglgansberger S. Development of physical dependence on morphine in respect to time and dosages and quantification of the precipitated withdrawal syndrome in rats. Psychopharmacologia (Berl.) 1973; 33: 19–38
   PubMed Web of Science ®Google Scholar
• Borden E. C., Ball L. A. Interferon: biochemical, cell growth inhibitory. and immunobiological effects. Progress in hematology, E. Brown. Grune and Stratton, New York 1981; Vol. 12: 299–339
   Google Scholar
• Carter W. A. Mechanisms of cross‐species activity on mammalian interferon. Pharmacology and Therapeutics 1979; 7: 245–251
   PubMed Web of Science ®Google Scholar
• Cohen M., Keats A. S., Krivoy W., Ungar G. Effect of actinomycin D on morphine tolerance. Proceedings of the Society for Experimental Biology und Medicine 1965; 119: 381–384
   PubMed Web of Science ®Google Scholar
• Collier H. O. J. Consequences of interaction between opioid molecule and specific receptor. Mechanisms of pain rind analgesic compounds, R. F. Beers, Jr., E. G. Basset. Raven Press, New York 1979; 339–359
   Google Scholar
• Dafny N. Modification of morphine withdrawal by interferon. Life Sciences 1983a; 32: 303–305
   PubMed Web of Science ®Google Scholar
• Dafny N. Interferon modifies morphine withdrawal phenomena in rodents. Neuropharmacology 1983b; 22: 647–651
   PubMed Web of Science ®Google Scholar
• Dafny N. Interferon modifies EEG and EEG‐like activity recorded from sensory, motor and limbic system structures in freely behaving rats. Neurotoxicology 1983c; 4: 235–240
   PubMed Web of Science ®Google Scholar
• Dafny N., Reyes‐Vazquez C. Three different types of α‐interferons alter naloxone‐induced abstinence in morphine‐addicted rats. Immunopharmacology 1085; 9: 13–17
   Google Scholar
• Dafny N., Prieto‐Gomez B., Reyes‐Vazquez C. Does the immune system communicate with the central nervous system: Interferon modifies central nervous activity. Journal of Neuroimmunology 1985; 9: 1–12
   PubMed Web of Science ®Google Scholar
• Dafny N., Zielinski M., Reyes‐Vazques C. Alteration of morphine withdrawal to naloxone by interferon. Neuropeptides 1983; 3: 453–463
   PubMed Web of Science ®Google Scholar
• Gilman S. C., Schwartz J. M., Milner R. J., Bloom F. E., Feldman J. D. β‐endorphin enhances lymphocyte proliferative responses. Proceedings of the National Academy of Science, USA 1982; 79: 4226–4230
   PubMed Web of Science ®Google Scholar
• Gutterman J. U., Fine S., Quesada J., Homing S. J., Levine J. F., Alexanian R., Bernhardt L., Kramer M., Speigel H., Colburn W., Trown P., Merigan T., Dziewanoski A. Recombinant leukocyte A interferon: pharmacokinetics, single‐dose tolerance, and biological effects in cancer patients. Annals of Internal Medicine 1982; 96: 549–556
   PubMed Web of Science ®Google Scholar
• Hazum E., Chang K. ‐J., Cuatrecasus P. Specific nonopiate receptors for P‐endorphin. Science 1979; 205: 1033–1035
   PubMed Web of Science ®Google Scholar
• Herberman R. B., Ortaldo J. R., Bonnard G. D. Augmentation by interferon of human natural and antibody‐dependent cell‐mediated cytotoxicity. Nature 1979; 277: 221–223
   PubMed Web of Science ®Google Scholar
• Hogdson J. R., Bristow R. L., Castles T. R. Repression of RNA transcription during the development of analgesic tolerance to morphine. Nature 1974; 248: 671–673
   PubMed Web of Science ®Google Scholar
• Huddlestone J. R., Merigan T. C., Oldstone M. B. A. Induction and kinetics of natural killer cells in humans following interferon therapy. Nature 1979; 282: 417–419
   PubMed Web of Science ®Google Scholar
• Hung C. Y., Lefkowitz S. S., Geber W. F. Interferon inhibition by narcotic analgesics. Proceedings of the Society for Experimental Biology und Medicine 1973; 142: 106–111
   PubMed Web of Science ®Google Scholar
• Isaacs A., Lindenmann J. Virus interference: 1. The Interferons. Proceedings of the Royal Society of London (Biology) 1957; 147: 258–267
   PubMed Web of Science ®Google Scholar
• Jaffe J. H., Martin W. R. Opioid analgesics and antagonists. The pharmacological basis of therapeuticsSix Edition, A. G. Gilman, L. S. Goodman, A. Gilman. Macmillan Publishing Co., Inc., New York 1980; 497–534
   Google Scholar
• Kerr F. W. L., Pozuelo J. Suppression of physical dependence and induction of hypersensitivity to morphine by stereotaxic hypothalamic lesions in addicted rats. Mayo Clinic Proceedings 1971; 46: 653–665
   PubMed Web of Science ®Google Scholar
• Laschka E., Herz A., Blasig J. Sites of action of morphine involved in the development ot physical dependence in rats. I. Comparison of precipitated morphine withdrawal after intraperitoneal and intraventricular injection of morphine antagonists. Psychopharmacologia (Berl.) 1976; 46: 133–139
   PubMedGoogle Scholar
• Lopker A., Abood L. G., Hoss W., Lionetti F. J. Stereoselective muscarinic acetylcholine and opiate receptors in human phagocytic leukocytes. Biochemical Pharmacology 1980; 29: 1361–1365
   PubMed Web of Science ®Google Scholar
• Louria D. B. Medical complications of pleasure‐giving drugs. Archives of Infernal Medicine 1969; 123: 82–87
   PubMed Web of Science ®Google Scholar
• Mathews P. M., Froelich J. C., Sibbit W. L., Bankhurst A. D. Enhancement of natural cytotoxicity by β‐endorphin. Journal of Immunology 1983; 130: 1658–1662
   PubMed Web of Science ®Google Scholar
• McCain H. W., Lamster I. B., Bozzone J. M., Grbic J. T. β‐endorphin modulates human immune activity via non‐opiate receptor mechanisms. Lye Sciences 1982; 31: 1619–1624
   PubMed Web of Science ®Google Scholar
• Pollard R. B. Usages of interferon and interferon inducers in man: the second half of 1980. Medical Biology 1981; 59: 69–16
   PubMedGoogle Scholar
• Prieto‐Gomez B., Reyes‐Vazquez C., Dafny N. Differential effects of interferon on ventromedial hypothalamus and dorsal hippocampus. Journal of Neuroscience Research 1983; 10: 273–278
   PubMed Web of Science ®Google Scholar
• Rasmussen L., Merigan T. C. Effect of interferon therapy on circulating lymphocytes in humans. Journal of Interferon Research 1980; 1: 101–110
   PubMedGoogle Scholar
• Reyes‐Vazuez C., Prieto‐Gomez B., Dafny N. Novel effects of interferon on the brain: Microiontophoretic application and single cell recording. Neuroscience Letters 1982; 34: 201–206
   PubMed Web of Science ®Google Scholar
• Reyes‐Vazquez C., Prieto‐Gomez B., Dafny N. Alpha and gamma interferons' effects on cortical and hippocampal neurons: Microiontophoretic application and single cell recording. International Journal of Neuroscience 1984a; 25: 113–121
   PubMed Web of Science ®Google Scholar
• Reyes‐Vazquez C., Weisbrodt N., Dafny N. Does interferon exert its actions through opiate receptors. Life Sciences 1984b; 35: 1015–1021
   PubMed Web of Science ®Google Scholar
• Scott G. M., Secher D. S., Flowers D., Bate J., Cantell K., Tyrrell D. A. J. Toxicity of interferon. British Medical Journal 1981; 282: 1345–1348
   PubMed Web of Science ®Google Scholar
• Shavit Y., Lewis J. W., Terman W. G., Gale K. P., Liebeskind J. C. Opioid peptides mediate the suppressive effect of stress on natural killer cell cytotoxicity. Science 1984; 223: 188–190
   PubMed Web of Science ®Google Scholar
• Smalley R. V., Oldham R. K. Interferon as a biological response modifying agent in clinical trials. Journal of Biological Response Modifiers 1983; 2: 401–408
   PubMedGoogle Scholar
• Stewart J. J. The interferon system. Springer‐Verlag, New York 1979; 292–304
   Google Scholar
• Teitelbaum H., Catravas G. N., McFarland W. L. Reversal of morphine tolerance after medial thalamic lesions in the rat. Science 1974; 185: 449–451
   PubMed Web of Science ®Google Scholar
• Trinchieri G., Santoli D., Koprowski H. Spontaneous cell‐mediated cytotoxicity in humans: role of interferon and immunoglobulins. Journal of Immunobiology 1978; 120: 1849–1855
   PubMed Web of Science ®Google Scholar
• Vilcek J., Ng M. H., Friedman‐Klein A. E., Krawciw T. Induction of interferon synthesis by synthetic double‐stranded polynucleotides. Journal of Virology 1986; 2: 648–650
   Google Scholar
• Wei E. Quantification of precipitated abstinence in morphine dependent rats. Federation Proceedings 1971; 31: 527, Abs.
   Google Scholar
• Wei E., Way E. L. Application of the pellet implantation technique for the assessment of tolerance and physical dependence in the rodent. Methods in narcotics research, S. Ehrenpreis, A. Neidle. Marcel Dekker. Inc., New York 1975; 243–259
   Google Scholar
• Weinstein Y., Brodeus B. R., Melman K. L., Merigan T. C. Interferon inhibition of lymphocyte mitogenesis. Immunobiology 1977; 33: 313–319
   Google Scholar
• Wybran J., Appelboom T., Famaey J. ‐P., Govaerts A. Suggestive evidence for methionine‐enkephalin on normal human blood T lymphocytes. Journal of Immunology 1979; 123: 1068–1070
   PubMed Web of Science ®Google Scholar